Product details
Background：Programmed cell death protein-1 (PD-1) is an inhibitory immune checkpoint primarily expressed by immune cells. In the tumor microenvironment, PD-1 binds to its ligands PD-L1 and PD-L2, inhibiting T cell activation and proliferation, which allows tumor cells to evade immune system surveillance. Peresolimab, a monoclonal antibody against PD-1(programmed death protein 1) , falls into the category of immune checkpoint inhibitors. It is mainly used in cancer therapy, by blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, enhance the body’s immune system against tumor cells.
